EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) granted non‑statutory inducement stock options to fourteen new employees to purchase an aggregate of 362,500 shares, granted on April 15, 2026 under Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $14.63 (closing price on April 15, 2026), a 10‑year term and vest over four years: 25% on the first anniversary and the remainder in equal monthly installments, subject to continued service. Grants were approved by the Compensation Committee.

AI-generated analysis. Not financial advice.

Positive

• Inducement grants on 362,500 shares bolster hiring and employee retention
• Exercise price set at $14.63 ties cost to market price on grant date

Negative

• Potential dilution from 362,500 share options outstanding until exercise
• Long 10‑year option term extends potential dilution and outstanding share overhang

News Market Reaction – EYPT

+0.81%

1 alert

+0.81% News Effect

On the day this news was published, EYPT gained 0.81%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement option shares: 362,500 shares Number of employees: 14 employees Exercise price: $14.63 per share +3 more

6 metrics

Inducement option shares 362,500 shares Aggregate options granted to fourteen new employees

Number of employees 14 employees Recipients of inducement stock option awards

Exercise price $14.63 per share Closing price of common stock on April 15, 2026

Option term 10 years Contractual life of inducement stock options

Vesting period 4 years Standard vesting schedule for the granted options

Initial vesting tranche 25% of shares Vests on first anniversary of each employee’s grant date

Market Reality Check

Price: $13.66 Vol: Volume 496,503 is below t...

low vol

$13.66 Last Close

Volume Volume 496,503 is below the 20-day average of 909,458 (relative volume 0.55x). low

Technical Shares trade above the 200-day moving average at 13.52, with current price at 14.64.

Peers on Argus

EYPT gained 2.02% while close peers showed mixed, mostly modest moves (e.g., OCS...

1 Down

EYPT gained 2.02% while close peers showed mixed, mostly modest moves (e.g., OCS up 0.11%, PRAX down 2.33%, UPB down 5%). Momentum scanner flagged only 1 biotech peer (SANA) moving down, supporting a stock-specific move.

Historical Context

5 past events · Latest: Mar 16 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 16	Inducement grants	Neutral	+1.6%	Inducement stock options for new hires under NASDAQ Listing Rule 5635(c)(4).
Mar 04	Earnings results	Negative	-1.8%	Weaker FY 2025 revenue and wider net loss amid higher Phase 3 spending.
Mar 02	Clinical trial update	Positive	+4.4%	First patients dosed in two global Phase 3 DURAVYU DME trials.
Feb 25	Earnings date set	Neutral	+4.2%	Announcement of date and webcast details for Q4 and FY 2025 results.
Feb 24	Conference participation	Neutral	-0.1%	Planned management participation in multiple March investor conferences.

Pattern Detected

Recent news events, including prior inducement grants, clinical updates, and earnings, have generally seen price moves aligned with the news tone, without clear divergence patterns.

Recent Company History

Over the past few months, EyePoint has combined routine corporate actions with major clinical and financial updates. A prior inducement grant on Mar 13, 2026 for 20,000 shares saw a modestly positive move. Clinical progress included first patients dosed in two global Phase 3 DURAVYU DME trials announced on Mar 2, 2026, which was followed by a positive reaction. Earnings and full‑year 2025 results on Mar 4, 2026 brought weaker financials and a slight decline. Today’s inducement awards continue the pattern of equity‑based hiring incentives.

Market Pulse Summary

This announcement details routine inducement equity awards, granting 362,500 non‑statutory stock opt...

Analysis

This announcement details routine inducement equity awards, granting 362,500 non‑statutory stock options to fourteen new employees at an exercise price of $14.63 and a 10‑year term. Vesting occurs over 4 years, beginning with 25% after one year, then monthly thereafter. Against a backdrop of ongoing Phase 3 clinical programs and recent capital markets activity, investors may track cumulative option grants, hiring trends, and subsequent SEC filings for additional dilution and governance context.

Key Terms

non-statutory stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-statutory stock options financial

"the Company granted non-statutory stock options to new employees as inducement awards"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

nasdaq listing rule 5635(c)(4) regulatory

"outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 362,500 shares of EyePoint common stock to fourteen new employees. The stock options were granted on April 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $14.63 per share, the closing price of EyePoint’s common stock on April 15, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU^™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:
Green Room Communications
Direct: 850-384-2833
EyePointMedia@grcomms.com

FAQ

What did EyePoint (EYPT) announce about inducement stock option grants on April 16, 2026?

They granted non‑statutory options totaling 362,500 shares to fourteen new employees on April 15, 2026. According to the company, grants were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4).

What are the exercise price and term for the EyePoint (EYPT) inducement options?

The options have an exercise price of $14.63 and a 10‑year term. According to the company, $14.63 was the closing price on April 15, 2026 and applies to all awarded options.

How do the EyePoint (EYPT) inducement options vest for new employees?

Options vest over four years: 25% after one year, then monthly over three years. According to the company, vesting is subject to continuous employment through each vesting date.

How many employees received inducement awards and how many shares were granted by EyePoint (EYPT)?

Fourteen new employees received options covering an aggregate of 362,500 shares. According to the company, the grants were made as material inducements for each employee to join EyePoint.

What shareholder impact should investors expect from EyePoint's (EYPT) April 2026 inducement grants?

Investors should expect potential dilution from 362,500 options outstanding until exercised. According to the company, these are inducement awards priced at market and subject to multi‑year vesting and exercise timelines.